Michele Strykowsky
Women's Health · Voorhees, NJNPI 1497394878
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Astellas Pharma US Inc at 27.2% of the total.
Across 53 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$306
- AbbVie$252
- Exeltis, USA Inc.$184
- Exact Sciences$59
- Myriad Women's Health, Inc.$54
- Organon$34
- plus $235 from 12 others
What the payments were for
- Food & beverage$1,124100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 14 | $306 |
| AbbVie | 11 | $252 |
| Exeltis, USA Inc. | 9 | $184 |
| Exact Sciences | 3 | $59 |
| Myriad Women's Health, Inc. | 1 | $54 |
| Organon | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Agile Therapeutics, Inc. | 2 | $30 |
| Evofem Biosciences, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $19 |
| Smith+Nephew | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $18 |
| Myovant Sciences Inc. | 1 | $17 |
| Mylan Pharmaceuticals Inc. | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Therapeuticsmd, Inc. | 1 | $14 |
| Medicem Inc. | 1 | $14 |
| Merck | 1 | $14 |
How this compares
$1,124 in reported general payments places this provider in the 85th percentile of 182 women's health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 19 | $1,988 |
| ValacyclovirValacyclovir Hcl | 27 | $839 |
| Medroxyprogesterone Acetate | 25 | $834 |
| Metronidazole | 17 | $267 |
| Norgestimate-Ethinyl Estradiol | 14 | $112 |
| Fluconazole | 22 | $102 |
| Gabapentin | 13 | $44 |
Paid to pharmacies, not to this prescriber.
Other women's health in Voorhees
- Caty MilanoVoorhees$1K
- Tara AllenVoorhees$1K
- Brianna CasamassimaVoorhees$745
- Gillian GoreeVoorhees$541
- Kathie OlsonLawrenceville$5K
- Valerie FultonPennsauken$5K
- Patience AssobmoNewark$5K
- Lorraine HarrisPennsauken$4K
- Edita LuansingRidgewood$4K
- Seton CiagliaOradell$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.